To re-confirm the involvement of IL-1β mediated NF-κB signaling in drug resistance, we designed another experimental set-up where EP and LP cancer cells were exposed to aspirin (ASP; 10 mM), an inhibitor of NF-κB activation and MRP1 was evaluated by flow-cytometry. Here, NFKB1 is linked to cancer.